PLSE Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -3.03%, SMA50 16.32%, SMA200 19.6%). The stock’s 14-day RSI is 50.26 (neutral), while the ATR of 1.74 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.65% below its high and over 53.58% above its low. Average 10-day trading volume of 431.01 thousand shares is slightly above the 3-month average of 383.44 thousand, indicating heightened recent market interest.

Pulse Biosciences, Inc. generated EPS of -$1.08 over the past year. Five-year average earnings growth is 12.82%. Wall Street analysts project EPS growth of -1.54% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $32.00. The high target offers -24.55% upside. The low target suggests -24.55% downside. The mean target is $32.00. This offers -24.55% upside. Pulse Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by 22.73%. The prior quarter beat by -15.62%. Over the last six quarters, Apple has recorded several small beats. These include -29.17% in March 27, 2025.

Pulse Biosciences, Inc. has 69.21 million shares outstanding. The public float is 18.48 million shares, elevated short interest at 15.04% of float. This equals 2.89 million shares. The short ratio is 8.38 days. Institutional investors hold 45.95% of the float. Insiders own 73.21%. DUGGAN ROBERT W holds 48.21 million shares, UECKER DARRIN has 122.87 thousand shares and Zanganeh Maky has 86.67 thousand shares. Over the past six months, insider transactions show net selling. They sold 125.00 thousand shares across 7 transactions.

Pulse Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading above this model’s fair value.

Pulse Biosciences, Inc. (NASDAQ:PLSE) closed at $42.41 USD, gaining $4.17 (10.90%) from the previous close of $38.24. The stock is currently mid-range between its 52-week high and low $12.56 and $45.90. With a market capitalization of about $2.94 billion, Pulse Biosciences, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.65). Key stats such as the average daily volume over the past year has been around 384.67 thousand shares, trading with heavier-than-usual volume. Headquartered in Miami, FL, Pulse Biosciences, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Paul Arthur LaViolette, the company employs approximately 116 people and listed since May 18, 2016. Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine.

Pulse Biosciences, Inc. trades at a P/E ratio of -35.57, slightly below the S&P 500 average, with a price-to-sales ratio of 2430.39 and a price-to-book ratio of 28.94 reflecting a rich premium to book value. The P/FCF stands at -37.89, also below market averages. Compared to sector medians, Pulse Biosciences, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares are flat 0.73% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pulse Biosciences, Inc. trading at a premium to the broader market with a P/E of -35.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.38, suggesting -37.8% downside. Our AI forecast model points to short-term strength (11.11% over two weeks), a medium-term fall (-9.6% over three months), and a longer-term loss (-0.07% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Pulse Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.11%, with price expected at $47.12 by August 21, 2026, within a range of $45.58 to $48.72 3-Month Outlook: Projected fall of -9.6%, reaching $38.34 by November 04, 2026, with a range of $36.39 to $40.17. 1-Year Outlook: Projected loss of -0.07%, with price at $42.38 by August 06, 2027, within a range of $41.05 to $43.88.